Stifel initiated coverage of Alamar Biosciences (ALMR) with a Buy rating and $28 price target Alamar is an emerging multiplex proteomics player that has seen rapid adoption of its ARGO platform in a short period of time, the analyst tells investors in a research note. Stifel expects ramping usage in key fields like neuroscience to drive near- and mid-term strength for the company.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMR:
- Opening Day: HawkEye 360 jumps in debut after high‑end pricing
- Alamar Biosciences reports Q1 EPS ($1.74) vs. (68c) last year
- Opening Day: Drone maker AEVEX pops on debut
- Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today
- Alamar Biosciences opens at $22.60, IPO priced at $17 per share